This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Thomas A. Pearson, MD, PhD

JAMA. 1998;279:1659-1661.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of THE JOURNAL, Downs et al¹ present the primary results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). The study is yet another randomized, placebo-controlled, clinical trial of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, in this case lovastatin, as a means to prevent atherosclerotic coronary artery disease. Although readers might wonder what such a trial might add to understanding the role of lipid-lowering therapy in general, or of the use of the so-called statins in particular, this trial is of singular importance and timeliness to guide the use of these agents in the controversial area of the primary prevention of cardiovascular disease.

AFCAPS/TexCAPS enters a field crowded by superbly conceived and implemented clinical trials, usually industry-funded but carried out independently by highly skilled teams from academia. AFCAPS/TexCAPS is no exception. However, examination of these clinical trials from the viewpoint of . . . [Full Text of this Article]

From the University of Rochester School of Medicine, Rochester, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial
I. U. Haq, E. J. Wallis, W. W. Yeo, P. R. Jackson, L. E. Ramsay, Louis H. Krut, David E. Kandzari, Pascal J. Goldschmidt-Clermont, James M. Mason, Nick Freemantle, Todd D. McDiarmid, William A. Hensel, John A. Papadakis, Dimitri P. Mikhailidis, Judith Walsh, David Siegel, Arthur L. M. Swislocki, John R. Downs, Antonio M. Gotto, Jr, Michael Clearfield, Stephen Weis, Robert S. Rosenson, and Christine C. Tangney
JAMA. 1999;281(5):414-419.
EXTRACT | FULL TEXT  

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs, Michael Clearfield, Stephen Weis, Edwin Whitney, Deborah R. Shapiro, Polly A. Beere, Alexandra Langendorfer, Evan A. Stein, William Kruyer, Antonio M. Gotto, Jr, and for the AFCAPS/TexCAPS Research Group
JAMA. 1998;279(20):1615-1622.
ABSTRACT | FULL TEXT  

Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Robert S. Rosenson and Christine C. Tangney
JAMA. 1998;279(20):1643-1650.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong
QJM 2005;98:599-614.
ABSTRACT | FULL TEXT  

Primary Prevention of Coronary Heart Disease
Ballantyne
J. Clin. Endocrinol. Metab. 2000;85:2089-2092.
FULL TEXT  

Update in Preventive Medicine
Merenstein
ANN INTERN MED 2000;132:844-845.
FULL TEXT  

Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data
Jacobson et al.
Arch Intern Med 2000;160:1361-1369.
ABSTRACT | FULL TEXT  

Reply to EG Bliznakov
Heber
Am. J. Clin. Nutr. 2000;71:153-154.
FULL TEXT  

Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial
Haq et al.
JAMA 1999;281:414-419.
FULL TEXT  

Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement
Heber et al.
Am. J. Clin. Nutr. 1999;69:231-236.
ABSTRACT | FULL TEXT  

Lovastatin Reduces Coronary Events in Patients with Average Cholesterol Levels
JWatch Women's Health 1998;1998:4-4.
FULL TEXT